PC 786

Drug Profile

PC 786

Alternative Names: PC786

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Pulmocide
  • Class Antivirals; Small molecules
  • Mechanism of Action Polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 26 Oct 2016 Preclinical data in Respiratory Syncytial Virus infection presented at the IDWeek 2016 (IDW - 2016)
  • 03 Sep 2016 Preclinical data in Respiratory Syncytial Virus infection presented at the 26th Annual Congress of the European Respiratory Society (ERS - 2016)
  • 08 Jun 2016 Pulmocide plans a phase I trial for Respiratory Syncytial Virus infection in United Kingdom (Pulmocide website, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top